MaxCyte, Inc. Save the Date: Capital Markets Day
May 29 2019 - 2:00AM
RNS Non-Regulatory
TIDMMXCT
MaxCyte, Inc.
29 May 2019
MaxCyte, Inc.
("MaxCyte" or the "Company")
Save the Date: Capital Markets Day
Gaithersburg, Maryland - 29 MAY 2019: MaxCyte (LSE: MXCT, MXCS),
the global cell-based medicines and life sciences company, will
host a Capital Markets Day for analysts and institutional investors
on Thursday 11 July, from 15.00 - 17.30 BST in London.
Discussion topics will include MaxCyte's partner programmes and
in-house oncology pipeline, and trends in the cell therapy
industry. Demonstrations will also be given of the Company's new
products. Light refreshments will be available after the
presentations, with the opportunity for an informal Q&A with
the MaxCyte management team.
Further details of the event will follow.
To register your interest or for more information, please
contact Sarah Downing on 020 7886 2910 or via email at
sarah.downing@panmure.com.
About MaxCyte
MaxCyte is a global clinical-stage cell-based therapies and life
sciences company applying its proprietary cell engineering platform
to deliver the advances of cell-based therapy to patients with high
unmet medical needs. MaxCyte is developing novel CARMA(TM)
therapies for its own pipeline, with its first drug candidate in a
Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary
therapeutic platform for autologous cell therapy for the treatment
of solid cancers. In addition, through its life sciences business,
MaxCyte leverages its Flow Electroporation(R) Technology to enable
its biopharmaceutical partners to advance the development of
innovative medicines, particularly in cell therapy. MaxCyte has
placed its flow electroporation instruments worldwide, with all of
the top ten global biopharmaceutical companies. The Company now has
more than 70 partnered programme licenses in cell therapy with more
than 35 licensed for clinical use, including four announced
commercial licenses covering potentially more than 30 products with
aggregate potential milestones of more than $250m plus significant
additional potential milestones from the multi-drug commercial
agreement with Kite announced 1 March 2019. With its robust
delivery technology platform, MaxCyte helps its partners to unlock
the full potential of their products. For more information, visit
www.maxcyte.com.
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer +1 301 944 1660
Nominated Adviser and Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
James Stearns +44 (0)20 7886 2500
Financial PR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh
Sukaina Virji
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRADMGZKMRZGLZZ
(END) Dow Jones Newswires
May 29, 2019 02:00 ET (06:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024